Loading clinical trials...
Loading clinical trials...
A Pilot Evaluation of Ponatinib (AP24534), a Potent Oral Pan-FGFR Inhibitor, in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma: a Multi-Institutional Study
Conditions
Interventions
Ponatinib
Start Date
January 1, 2016
Primary Completion Date
July 1, 2018
Completion Date
July 1, 2023
Last Updated
December 18, 2015
NCT07046923
NCT05129969
NCT05770102
NCT07114653
NCT07040657
NCT06502743
Lead Sponsor
Washington University School of Medicine
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions